consumption of red and/or processed meat, and a history of diabetes. 2, 3 Epidermal growth factor receptor (EGFR) has been recognized as an effective anticancer target during the last few years. Monoclonal antibodies used to block EGFR in combination with chemotherapy or radiation have yielded improved outcomes in CRC patients with extended RAS wild-type tumors. Mutations in the RAS and BRAF genes are harmful to anti-EGFR therapy in metastatic CRC (mCRC). 4 RAS and BRAF oncogene mutations are mutually exclusive and occur in 36.97% and 4.24% of CRC patients, respectively, as described in our previous work. 5 Thus, identifying the unique genomic profiles and molecular phenotypes could help effectively establish the best treatment method in patients with anti-EGFR therapy resistance. CRC is one of the most interesting fields of next-generation sequencing (NGS) application. The number of studies employing the NGS technique continues to increase. The Cancer Genome Atlas (TCGA) project studied more than 224 CRC cases and showed that 24 genes, including APC, TP53, SMAD4, PIK3CA, and KRAS, contained significant mutations. Three genes (ARID1A, SOX9, and FAM123B/ WTX) were frequently mutated. 6 Ashktorab et al analyzed 63
Iranian patients using targeted exome sequencing and found higher mutation rates of MSH3, MSH6, APC, and PIK3CA and hypothesized a larger role for these genes in CRC. They suggested the adoption of a specific informed genetic diagnostic protocol and tailored therapy in this population. 7 Because patients with RAS wild-type CRC can be non-responders to EGFR-targeted therapy, Geibler et al analyzed cell lines and tumor specimens to identify prediction markers by NGS, EGFR methylation and expression, and E-cadherin expression. The authors revealed ATM mutations and low E-cadherin expression as novel supportive predictive markers. 8 Adua et al analyzed primary tumor and liver metastasis samples from 7 KRAS wild-type patients and compared the genotypes of 22 genes associated with anti-EGFR before and after chemotherapy. The results showed marked genotypic differences between pre-and post-treatment samples, which were likely attributable to tumor cell clones selected by therapy. 9 Gong et al analyzed 315 cancer-related genes and introns of 28 frequently rearranged genes in 138 mCRC cases using FoundationOne. They identified a novel KRAS mutation (R68S) associated with an aggressive phenotype. The authors reported that ERBB2-amplified tumors may benefit from anti-HER2 therapy, and hypermutated tumors or tumors with high tumor mutational burden with MSI-H or POLE mutation may benefit from anti-PD-1 therapy.
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This study examined genetic alterations in CRC in a Taiwanese population. We performed whole-exome sequencing (WES) to detect the mutational status in all human protein-coding genes using fresh frozen tissue from 32 Taiwanese patients with CRC. 
| MATERIALS AND METHODS

| Study patients and tumor samples
| WES analysis and coverage
Using massive parallel sequencing on a NextSeq platform, we generated a mean of 157 M raw reads per sample, of which 141 M were aligned to the human reference genome (hg19; Table 2 ). The mean depth of the target regions for the 32 samples was 119× (range 34.79-197.53×). The coverage of the target regions exceeded 97.97%. Figure 1 is an overview of our approach used to identifying variants.
| CRC-associated oncogene variants
| RAS mutations
Overall, RAS mutations were present in 28.13% of our CRC patients ( Figure 2 ). The most common RAS mutations were KRAS mutations in exon 2 (codons 12 and 13), including G12V (44.44%), G12C (11.11%), and G13D (11.11%).
Beyond the well-established point mutations in codons 12 and 13 of exon 2 of KRAS, we identified mutations in codon 117 of exon 4 (K117N, 11.11%) and codon 146 of exon 4 (A146T, 11.11%). One mutation (11.11%) in codon 68 (exon 3) of NRAS was also detected; this was a novel alteration (R68I). The non-synonymous variant at locus 115256508 had a C-to-A change mapped in the small GTP-binding protein domain, with an allele fraction of 21.19% (total reads 118, variant count 25) ( Figure S1A ). Together, these non-KRAS exon 2 mutations constituted 33.33% of all RAS mutations ( Figure 3 ).
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| RAF mutations
Two RAF mutations were found in 9.38% of our patients ( Figure 2 ). Two patients (6.25%) had BRAF V600E mutations. One patient (3.13%) had an ARAF T256fs mutation.
None of the CRC patients with RAS mutations harbored a concomitant mutation in RAF. The remaining patients (62.5%) were RAS/RAF wild-type (Figure 2 ).
| PIK3CA mutations
Three patients (9.38%) had PIK3CA mutation tumors. The mutation variants were R38S, G118D, and D350Y; D350Y was a novel mutation. The non-synonymous variant at locus 178921566 had a G-to-T change mapped in the phosphatidylinositol 3-kinase, C2 domain, with an allele fraction of 17.53% (total reads 97, variant count 17) ( Figure S1B ).
| TCF7L2 mutations
Two patients (6.25%) had TCF7L2 mutation tumors. The identified variants were R471C, F357L, and G424E, and each patient had two of the three TCF7L2 variants.
| SOX9 mutations
Three patients (9.38%) had SOX9 frameshift mutations. One patient had an S431fs mutation, another a G484fs mutation,
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| CRC-associated tumor suppressor gene variants
| APC mutations
In total, we identified 19 patients (59.38%) with APC alterations. A total of 26 APC mutations were identified in the 19 samples, most of which were nonsense mutations that introduced a premature stop codon (R283*, S320*, Q541*, R564*, R876*, R1114*, Q1294*, E1309*, Q1367*, Q1378*, R1450*, E1544*, Q1916*, and R2204*). Six variants were frameshift deletions (L620fs, D1297fs, E1306fs, G1312fs, E1374fs, and E1397fs), 5 were frameshift insertions (L540fs, L852fs, T1292fs, L1302fs, and E1554fs,), and 1 was a missense mutation (S1400L). Among these mutations, 7 novel mutations were found (L540fs, T1292fs, D1297fs, L1302fs, E1306fs, E1374fs, and Q1916*) ( Figure S1D ).
| TP53 mutations
Overall, TP53 mutations were present in 50% of our CRC patients. Fifteen TP53 mutations were identified in the 16 samples. All variants have been reported (L43fs, K132N, P151S, R175H, C176F, R196*, L206*, M237I, R245C, M246R, E258K, R273H, R273C, R282W, and R306*).
| FBXW7 mutations
Six of the 32 samples (18.75%) had a mutation in FBXW7. Four FBXW7 variants were found in the 6 samples. All variants have been reported (G80W, W307C, R347H, and R387C).
| SMAD4 mutations
Three patients (9.38%) had SMAD4 mutations. Two variants have been reported previously (G419R and R496H), and the other was novel (Y260_H261delins*). The frameshift variant at locus 48584605 had an A insertion with an allele fraction of 22.18% (total reads 284, variant count 63) ( Figure S1E ). E583* in MSH4, R265Q in PMS1, and L633I in PMS2. Among these, MSH3 A61delinsAAPA and E456K, MSH4 E583*, PMS1 R265Q, and PMS2 L633I were novel mutations ( Figure  S1F-I) . The numbers of variants discovered in the MMR wildtype and mutation carriers are listed in Tables S1 and S2 .
| Mismatch repair (MMR
| Altered signaling pathways in CRC
Based on our analytical approach, we identified multiple genes in the RTK-RAS, PI3K, TGF-β, WNT, and P53 pathways. The APC gene in the WNT pathway had relatively high levels of somatic mutations compared to genes in the RTK-RAS, PI3K, TGF-β, and P53 pathways. We found 10 different altered WNT pathway genes, including LRP5, FZD10, APC, AXIN2, FAM123B, CTNNB1, TCF7L2, SOX9, FBXW7, and ARID1A, confirming the importance of this pathway in CRC. We found that 78.13% of tumors had alterations in the WNT pathway. We also evaluated genetic alterations in the RTK-RAS, PI3K, TGF-β, and P53 pathways, with mutation rates of 40.63%, 15.63%, 18.75%, and 56.25%, respectively ( Figure 4 ).
| Pathway mutations and associations
We compared the clinicopathological data of CRC patients with mutations in mutation-related pathways. The RTK-RAS pathway mutation rate was significantly higher in patients with a tumor size ≤4 cm compared to those with a tumor of >4 cm (57.89% versus 15.38%, P = 0.028). No clinicopathological variables were significantly correlated with WNT, PI3K, TGF-β, or P53 pathway mutations (Table 3) .
| DISCUSSION
All of the mutated genes discussed in our study have been previously classified as driver genes that confer a selective growth advantage to tumor cells harboring the mutations. CRC is similar to other cancers with only one or multiple driver gene mutations. Tumors with only one driver mutation, always in an oncogene, and with multiple driver mutations contain a combination of oncogene and tumor suppressor gene mutations. 15 In our study, of the 4 samples with a single mutation ( cases, which is higher than the mutation rate detected in our study. 16 In 2012, the TCGA consortium reported that up to 93% of CRC cases involved at least 1 alteration in a known WNT regulator. 6 Hyperactivation of the WNT pathway initiates the development of CRC, which predominantly occurs through inactivation of the APC gene. 17 Several agents have been investigated to target this pathway, including WNT inhibitors (eg, Rofecoxib, PRI-724, CWP232291) and a monoclonal antibody against frizzled receptors (e.g., vanituctumab). 18 In addition to APC and SOX9, we also identified a novel mutation in AXIN2 (p.R459L) ( Figure S1J ). The AXIN2 mutation identified in the current study, R459, is located in the region that interacts with β-catenin. The frequency of alterations in the RTK-RAS and PI3K pathways was 40.63% and 15.63%, respectively. RTK-RAS and PI3K pathway mutations have been found in 60.7% and 30% of CRCs, respectively. 16 In a normal cell, RTK-RAS and PI3K pathways control cell proliferation, differentiation, and survival. 19, 20 In a malignant cell, constitutive and aberrant activation of components of these pathways lead to increased cell growth, survival, and metastasis. Small molecule inhibitors, such as Sorafenib and PLX4720, which are currently being used to target BRAF p.V600E, have been developed to target the RTK-RAS and PI3K pathways. NVP-BEZ235 and BGT226 are being used to target the PI3K pathway in various cancers. 21 In addition to NRAS and PIK3CA, we identified two novel mutations in ERBB2 (p.W9fs) and PIK3R1 (p.S147* and p.L161*) ( Figure S1K ,L). The PIK3R1 p.S147* and p.L161* mutations were mapped to the Rho GTPase-activating protein domain.
In our study population, the mutation rate of the TGF-β and P53 pathways was 18.75% and 56.25%, respectively. TGF-β and P53 pathway mutations have been described in 28.9% and 69% of CRCs, respectively. 16 The TGF-β signaling pathway has pleiotropic functions, including the regulation of cell growth, apoptosis, cell motility, and invasion. TGF-β signaling plays a key role in tumor initiation, development, and metastasis. Many TGF-β pathway inhibitors, such as antisense oligonucleotides, neutralizing antibodies, and receptor kinase inhibitors, have been used in preclinical trials. For example, galunisertib is a TGFβR1 inhibitor that prevents signal transduction. 22 Under cellular stress, such as DNA damage, oncogenes, oxidative free radicals, and UV irradiation, the P53 protein is activated. Activation of P53 can induce cell cycle arrest, senescence, and apoptosis. Small molecular inhibitors, such as MIs, nutlins, and RITA, have been tested as therapeutic agents in CRC by activating this pathway. 23 In addition to SMAD4, we identified a novel mutation in TGFBR2 (p.D549A) and ATM (p.E650*) ( Figure  S1M ,N). Our relatively low rate of mutations in these 5 critical pathways may reflect our small sample size. Most CRC samples can be grouped by WNT-, RTK-RAS-, P53-, TGF-β-, and PI3K-dysregulated pathways. In our study population, 3 samples (3/32, 9.38%) had no mutation in any of these pathways. However, in these 3 samples, 2 had alterations in the Notch signaling pathway (CTBP2, CREBBP, KAT2B, DVL2, and PSEN2). Deregulation of Notch signaling in CRC has been reported. 24 The third sample exhibited alterations in cell adhesion molecules (CNTN2, HLA-DRB1, HLA-DRB5, and NRXN3). This indicates that it may be necessary to identify other dysregulated pathways to achieve therapeutic benefits.
We also compared the clinicopathological data of CRC patients with the mutational status of important signaling pathways in cancerous tissues. RTK-RAS pathway mutations were correlated with tumor size (P = 0.028). These results suggest that tumor progression is not linked to increased genetic instability, although this may be due to our small sample size and fact that most cases were stage II (48.39% cases); we need to collect more samples to confirm our results.
In conclusion, we identified recurrent mutations in genes such as APC, TP53, KRAS, and FBXW7, as well as unreported mutations in NRAS, PIK3CA, SOX9, APC, SMAD4, MSH3, MSH4, PMS1 PMS2, AXIN2, ERBB2, PIK3R1, TGFBR2, and ATM in a group of Taiwanese CRC patients. The data presented herein provide more comprehensive characteristics of the top deadly disease and identify a possibility for treating it in a targeted way.
